1. Home
  2. HXHX vs AEON Comparison

HXHX vs AEON Comparison

Compare HXHX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.56

Market Cap

12.0M

Sector

Industrials

ML Signal

HOLD

Logo AEON Biopharma Inc.

AEON

AEON Biopharma Inc.

HOLD

Current Price

$1.09

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
AEON
Founded
2003
N/A
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
10.6M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
HXHX
AEON
Price
$0.56
$1.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.20
AVG Volume (30 Days)
17.1M
209.6K
Earning Date
02-18-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
1.80
N/A
EPS
0.30
N/A
Revenue
$34,088,144.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.86
N/A
Revenue Growth
32.57
N/A
52 Week Low
$0.33
$0.38
52 Week High
$6.29
$19.32

Technical Indicators

Market Signals
Indicator
HXHX
AEON
Relative Strength Index (RSI) 45.62 54.84
Support Level $0.51 $1.05
Resistance Level $0.94 $1.23
Average True Range (ATR) 0.22 0.09
MACD -0.01 0.01
Stochastic Oscillator 19.57 43.39

Price Performance

Historical Comparison
HXHX
AEON

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About AEON AEON Biopharma Inc.

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Share on Social Networks: